Abiopharma

🔍 Zinman Jon (Director)

Company: Keenova Therapeutics plc (NONE)

Report Date: 2026-01-01

Detailed Transactions and Holdings:

• Acquired 4,384 shares of Ordinary Shares (Direct)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,031.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 4,384 shares of Restricted Stock Units (Derivative)
  Date: 2026-01-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 35,570.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3, F4

Footnotes:

• F1: Each restricted stock unit (the "RSU") that was settled, was settled in ordinary shares of the Issuer at one share per RSU.
• F2: Shares are held directly by JZ Advisors LLC, a limited liability company, of which the Reporting Person is a 100% owner and managing member.
• F3: On February 19, 2024, the Reporting Person was granted 10,942 RSUs vesting ratably on each of the first three anniversaries of January 1, 2024. Outstanding RSUs were subsequently adjusted as described in footnote 4 below.
• F4: Reflects that the Reporting Person received 6,711 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health.
• REMARKS: This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.